Podcasts about investment highlights

Nikola Lazarov is the co-founder and CEO of Eilla AI, a tool that provides AI workers for private market intelligence. Nikola is an AI engineer who started his career at a London-based hedge fund, Marble Bar Asset Management, where he worked as a quant. He realized the value of AI in structuring unstructured data for private companies and decided to start a company almost three years ago. What Eilla AI Does While Nikola mentions that their target clients are investors and investment bankers, Eilla AI's tool does various tasks, such as finding competitors, analyzing their USP, target market, and financials. It also offers a solution for finding comparable transactions and conducting valuation reports. By searching for similar companies, it can determine their multiples, revenues, and valuations. The tool collects data from various data providers, including CrunchBase Zero and PitchBook, and scrapes it on its own. One of the most exciting solutions offered by Eilla AI is finding comparable transactions and doing valuation reports. This involves finding similar companies, analyzing their financials, average multiples, and what is driving these valuations. The tool automatically gathers and compares the data, providing valuable insights for startups, investors, and investment bankers. How Eilla AI Works The conversation turns to how it works. Nikola talks through using the software and explains the visuals on the screen, which includes tabs such as company, profile, competitor, research, buyer, selection, investment highlights, key questions, risks and mitigates, and a one-pager. The company profile page provides a consolidated set of information about the company, including its headquarters location, number of employees, founding status, total raised, and last transaction. The company description, industry, problem solved, key team members, funding, product, clients, business model, digital intelligence, and news are all included. The platform is similar to CrunchBase and other data aggregators, but it aggregates data from various sources, such as LinkedIn, their website, CrunchBase, and Capita. The platform also offers footnotes for each piece of data, allowing users to hover over it to see the source of the information. The platform also provides information on the website traffic, such as the source and the number of followers. Aggregating Data from Various Sources Nikola explains how the tool works using competitor research as the example to find the closest competitors to Pay Hawk. He explains that this process saves time and helps save time by aggregating data.  However, what differentiates Eilla AI is what happens on top of this aggregated data. It uses a proprietary database of in-depth product information to gather information from over 7 million companies, ranking them based on funding, cat count, and other factors. AI is used to determine the number of competitors and similar companies.  A Vertical View of Information Users can select a few companies to dive deeper into, and a vertical view allows for a comparison table. The table includes company name type, description, product description, headquarters location, team, year of founding, last round of funding, status, ownership status, detailed offering, unique selling proposition, and target market. The information is organized in a way that would take weeks to pull together. Users can use the vertical view to see the companies side by side. The platform also includes green dots on product descriptions to indicate high similarity and source information. This tool is unique in that it not only provides data but also replicates the workflow of competitor research. It offers insights such as a SWOT analysis on the strengths, weaknesses, opportunities, and threats of Pay Hawk versus its competitors. Product and Services The platform also includes a Products and Services tab with bullet points around PayHawk versus its competitors. Each product has a footnote where users can click to see the sources and scroll down to understand the differences between the two companies. Nikola also mentions the upcoming release of Cap IQ Financial, which includes important information like revenue, beta, valuation, and financials. The buyer selection tab is particularly interesting, as it shows all similar companies to Payco, including acquisitions and mergers. These companies are split into potential strategic buyers, competitors, and financial buyers. The tool also highlights the similarities between Pay Hawk and other companies, such as Visma and Instant, a platform that automates control for secure payments and trustworthy suppliers. The platform also assesses the financial capabilities of the company to buy companies like Pay Hawk. Eilla AI Features Eilla AI  Nikola explains that the platform aims to replicate the workflow of investors and investment bankers by breaking down complex workflows into simpler steps. This is done by breaking down data from various sources, such as data providers, CRMs, emails, and nodes. The goal is to provide a comprehensive overview of the company's funding, team, head count, product, services, USP, and detailed offering. The platform also offers a one-pager, which can be easily downloaded and viewed as a PDF. This information provides a detailed overview of the company's funding, team, head count, product, and services, as well as its unique selling points. The platform also provides a free seven-day trial for potential customers, such as corporate executives or business consultants looking for acquisitions. Eilla AI Pricing Schedule The pricing schedule is based on the number of requests per user and the amount of time spent on due diligence. For larger companies, the standard price is $98 per month per seat, while for smaller companies, it is $300 per month per user. The platform also offers a free seven-day trial for those interested in trying out the product without the need for sales meetings. Timestamps: 02:38: Overview of Eilla AI's Services  04:46: Demonstration of Eilla AI's Capabilities  09:50: Competitor Research and Insights  16:08: Buyer Selection and Investment Highlights  20:18: Key Questions and Risks Mitigation  22:09: Customer Base and Pricing  24:50: Conclusion and Next Steps    Links: https://Eilla.ai   Unleashed is produced by Umbrex, which has a mission of connecting independent management consultants with one another, creating opportunities for members to meet, build relationships, and share lessons learned. Learn more at www.umbrex.com.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Abingworth has invested in Trodelvy development in a deal with Gilead, where one of the investment firm's startups will work with Gilead to expand the cancer drug's label. Cure Ventures has backed a cell therapy startup called Kenai Therapeutics targeting Parkinson's, with $82 million raised and chaired by Jeff Jonas, a former CEO of Sage Therapeutics. Former Turning Point executives have started a new startup with Blossomhill, focusing on cancer and autoimmune diseases and raising over $170 million in funding. Lindus Health, co-founded by a Moderna co-founder Robert Langer, is aiming to address challenges in contract drug research. Ginkgo has acquired Proof Diagnostics, founded by Feng Zhang, to gain gene editing tools for making genetic medicines.In other news, there is an inside look at biotech financing tools, a theory on protein chirality, settlement agreements in price-fixing cases, and upcoming webinars on omnichannel HCP engagement and tech talent recruitment in the life sciences industry. Biopharma Dive provides insights and news on biotech and pharma trends, covering topics such as clinical trials, FDA approvals, gene therapy, drug pricing, and research partnerships.

Unlock the secrets of real estate syndication with a deep dive into the industry in my exclusive conversation with Lance Pederson, a prominent expert in the field. Lance shares his wealth of experience, particularly in Class B industrial properties in the Midwest, and unveils his latest venture, Passive Advantage – a cutting-edge software startup crafted to empower investors.Navigating the real estate landscape involves a myriad of risks, and Lance and I fearlessly dissect these challenges, emphasizing often-overlooked nuances, particularly within the dynamic industrial sector. Beyond the allure of potential returns, we delve into critical elements such as leases, tenants, and your individual risk tolerance. Our goal is to demystify real estate investment risks, providing you with a clear, actionable understanding.As the episode concludes, Lance offers a fresh perspective on customer needs and value delivery in real estate. Drawing from his success in software startups, he illuminates a new approach to real estate investing, emphasizing the pivotal role of understanding customers' needs in wealth creation. Whether you're a novice venturing into the world of real estate or a seasoned investor seeking a paradigm shift, this episode is a treasure trove of insights and expert advice. Remember, it's not just about listening – absorb and apply for real success in real estate investing!Ready to supercharge your real estate investment knowledge? Click the links below to dive deep into the full episodes.https://lifebridgecapital.com/2023/08/25/building-relationships-to-grow-your-business-lance-pederson/https://lifebridgecapital.com/2023/08/24/industrial-real-estate-trends-and-predictions-lance-pederson/VISIT OUR WEBSITEhttps://lifebridgecapital.com/Here are ways you can work with us here at Life Bridge Capital:⚡️START INVESTING TODAY: If you think that real estate syndication may be right for you, contact us today to learn more about our current investment opportunities: https://lifebridgecapital.com/investwithlbc⚡️Watch on YouTube: https://www.youtube.com/@TheRealEstateSyndicationShow

eResearch Corporation President & Director of Research Chris Thompson gives an overview of their latest update report on Canadian North Resources, a Canadian-based mineral exploration and development company that explores for minerals at its Ferguson Lake Project in Nunavut, Canada.Watch until the end of the Global One Media interview to know the investment highlights of Canadian North Resources.For more information, please visit: https://eresearch.com/Watch the full YouTube interview here: https://www.youtube.com/watch?v=ObGsScaCilAAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

We dive back into the archives and found some gems from 2 leading experts. Part 1Episode 1450 - Helping 66,000 People Create Financial Independence | Rich Fettke Watch the full interview: https://www.youtube.com/watch?v=aZY7juiWlKE Part 2Episode 1384 - How To Spot A Good Developer | Bob Voelker Watch the Full episode: https://www.youtube.com/watch?v=KrY9rhaNUkQ VISIT OUR WEBSITEhttps://lifebridgecapital.com/Here are ways you can work with us here at Life Bridge Capital:⚡️START INVESTING TODAY: If you think that real estate syndication may be right for you, contact us today to learn more about our current investment opportunities: https://lifebridgecapital.com/investwithlbc⚡️Watch on YouTube: https://www.youtube.com/@TheRealEstateSyndicationShow

Die Instone Real Estate Group AG ist ein im SDAX-notierter, dynamisch wachsender Immobilienentwickler, der von den Turbulenzen an den Kapitalmärkten nicht verschont blieb. Der Bereichsleiter für Business Development Burkhard Sawazki steht Frage und Antwort zu den aktuellen Themen rund um die Gesellschaft. ⌚ Timestamps: (0:00) Intro (1:01) -- Beginn der Unternehmenspräsentation -- (1:53) Unternehmensvorstellung (17:45) Investment Highlights (25:23) Aktuelle Geschäftsentwicklung & Ausblick (29:10) -- Beginn der Q&A-Session -- (29:27) Wie hat sich das Umfeld seit der Prognosesenkung entwickelt? (33:07) Wie sichert sich Instone gegen die Inflationsdynamik ab? (36:20) Wie realistisch ist eine komplette Umsetzung der Pipeline? (39:05) Geht kostengünstiges Bauen auf Kosten der Qualität? (41:09) Wie lange reichen die bestehenden Aufträge? (42:50) Wie lange dauert ein durchschnittliches Bauprojekt? (46:07) Wieviel mehr kosten energiesparende Immobilien im Bau? (48:47) Wie finanziert Instone seine Tätigkeiten? (50:27) Wie sieht der operative Cashflow dieses und nächstes Jahr aus? (52:02) Gibt es noch Neuprojekte unter KfW-55-Standard? (53:43) Warum wird aktuell überhaupt eine Dividende ausgezahlt? (58:42) Gibt es aktuell interessante Akquisitionsziele? (59:08) Wie bewerten Sie die Grundstücke der Consus Real Estate? (1:00:12) Steht eine Übernahme durch die ActivumSG Limited an? (1:04:33) Wie viele Privataktionäre haben Sie? (1:06:10) Fazit

This episode highlights two great conversations with Darin Batchelder and Denise Piazza. They will share how they scaled from passive to active real estate investments. Darin has a diverse background as a CPA, software sales executive, capital markets, loan trading, business owner, to multifamily syndication. He shares about the run-up to that first deal, including finding the perfect partner – someone more experienced from whom he learned a lot and who gave additional credibility to the deal. He also walks us through the process of starting out with passive investment to active investment by becoming a deal sponsor.Denise Piazza started both passive and active investments across multiple asset classes. Then she developed a passion for multifamily space and pursued a more active role as GP. In this episode, Denise details four things that have helped accelerate her transition from passive to active. She mentioned the importance of finding the right mentor with the complementary skill sets to hers, being disciplined and willing to sacrifice, and transparent. Key Points From This Episode: The value of starting off investing passively in other people's deals.The need to fully understand agreements and communications from deal sponsors.  It is more advantageous to invest in the multifamily asset class than in the stock market.  Darin's process of becoming a sponsor in his own right and learning to push through fear. The importance of building relationships with the broker community. Key considerations that might help you close that first deal, including the partner you choose.  One of the most important aspects that accelerated Denise's success in playing a role as a co-GP is her mentorship.Why did Denise go from passive to active investment?What helped accelerate her transition from passive to active?Links Mentioned in Today's Episode:Darin Batchelder Multifamily Real Estate Investing ShowDarin Batchelder's websiteMain Line Capital Advisors websiteEmail Denise PiazzaAbout Darin BatchelderDarin Batchelder is an entrepreneur, multifamily syndicator, real estate investor, and the owner of TZK Capital. From trading loan portfolios to syndicating multifamily deals, Darin has a diverse background as a CPA, software sales executive, capital markets, loan trading, business, and multifamily syndication. He has been the lead sponsor on 76 unit townhome community, key principal on FNMA non-recourse loan on 154 unit apartment community, and limited partner in 14 properties with 3,944 multifamily units.About Denise PiazzaDenise Piazza has 20 years of accounting, finance, and risk management experience and has managed teams of 30+ employees.  Denise has held several finance and accounting roles with top Fortune 100 companies on teams managing over $1B in acquisitions, joint ventures and disposition of assets.  Her experience in finance and accounting has made her highly skilled in analyzing data and developing financial models.  Denise has been investing in real estate for close to ten years in various asset classes as an active and passive investor.  Her experience with multiple asset classes has led to her passion for investing in multifamily assets and educating professionals on the benefits of diversifying their portfolios with assets that provide strong, predictable returns. She is now a limited partner in close to 1,200 units of multifamily assets. She runs a monthly real estate investing meetup group in Wayne, PA.

A recent report from the International Monetary Fund said there is a high risk of recession. It doesn't help too that inflation is on the rise, markets are unstable, and there is still the risk of a global health crisis. That's why, as real estate investors, it's important to invest in an asset class that is very resilient. Today, we look back at our conversations with Dan Kennedy and Charles Dobens who tell us why investing in multifamily is the best way forward.Dan shares his perspectives on the expenses of single-family versus those of multifamily and why he has had more joy with the latter. Meanwhile, Charles talks about why we should still be looking for deals, even during these uncertain times. Click the play button now and find out why multifamily is a resilient investment!

2:36 - Saudi Ministry of Investment Releases Q2 Investment Highlights Report; 49 Deals Worth More Than $925m Inked. Richard's one big thing is the release 13th edition of ”Investment Highlights.” The report examines investment developments and focuses the tourism sector. MISA says it oversaw 49 major deals valued at $925 million, which are set to create around 2000 new jobs in the local economy. The report includes an opening by H.E. Ahmed AlKhateeb, Minister of Tourism, and includes a dedicated section on tourism in Saudi Arabia, looking at the latest developments and opportunities driving this dynamic sector forward.10:03 - Saudi Arabia's STV released an interesting, forward-looking report on the opportunities for investors in the MENA region, particularly in startups. Lucien's one big thing is the report from STV, which says the MENA region is set to witness the birth of more than 45 unicorns in the next eight years, with an estimated total equity value to reach more than $100 billion, according to a new Saudi Technology Ventures (STV) report.The report from STV Insights highlights the opportunities for investing in the MENA region and Saudi Arabia and particular.  Saudi Arabia was described as the “gravitational center” for scaling tech unicorns, based on the country's GDP and stock exchange size.21:48 - The 966 welcomes Ahmed Shawly and Mostafa Fahmy from the Jeddah-based Wall of Sound record label and recording studio to talk about the young and growing music industry in Saudi Arabia, their entrepreneurial journey building the business from the ground up in a new industry with a blend of established and new, indie sounds, and so much more.1:17:00 - Yallah! Six top storylines to get you up to speed heading into the weekend.•Women to teach 4th grade elementary students in private and foreign schoolsThe ministry clarified in the circular that this decision vis-a-vis grade four comes in tandem with the success achieved after application of assigning the teaching of students from the first to third grades of elementary level of the private and foreign girls' schools to female teachers. “The ministry also desires to continue creating stimulating environments for teaching and learning as well as to support investment in the private general education sector,” it was stated in the circular…•Saudi Industry Minister: Percentage of National Products in Some Retail Stores Reaches 70%The largest local stores in the Kingdom began to allocate spaces within their distribution points and branches to highlight national products with the identity of the “Made in Saudi Arabia” Program to enhance the sale of local products and make them a preferred option for consumers, SPA said.•Aramco expands Namaat industrial investment programsThe Saudi Arabian Oil Company today announced a major expansion of its Namaat industrial investment programs, with 55 agreements and Memoranda of Understanding (MoUs) across the sustainability, digital, industrial, manufacturing and social innovation sectors. Namaat, which has grown from 32 to 55 investments since last year, supports industrial investment partnerships, helping to create jobs for Saudis and contributing to national growth and capacity building. The program aims to enable opportunities for local and international companies and leverage various incentives offered through the government's Shareek program and other initiatives.•Saudi Arabia to host international falcons exhibitionMore than half a million people will descend on the 2022 International Saudi Falcons and Hunting Exhibition, the world's largest falconry event, taking place from August 25 to September 3 in Riyadh, Saudi Arabia. The 10-day extravaganza brings together enthusiasts from around the globe and celebrates the art of falconry and its rich heritage, spanning generations in the Kingdom of Saudi Arabia. Visitors will get to see first-hand the world's finest collection of falcons and hunting equipment along with having the opportunity to experience unforgettable desert safari trips.•Saudi Arabia among top 5 overseas markets as ‘Bullet Train' rakes in $62.5MThe stylized action romp “Bullet Train,” starring Brad Pitt, earned $62.5 million worldwide over its opening weekend, according to studio estimates this week, with Saudi Arabia earning a spot on the overseas play ranking. The film racked up $32.4 million at the international box office and $30.1 million on the domestic charts. Overseas play was led by the UK with a $3.5 million start, followed by France at $3.1 million, Mexico delivering $3 million, Australia rolling to $2.2 million and Saudi Arabia clocking $1.9 million.•Ahead of Qatar World Cup, expanded Salwa border crossing inauguratedCapacity at the Salwa border crossing between Saudi Arabia and Qatar has been quadrupled from 3,000 cars to 12,000 cars in each direction per day.  The Salwa border post reopened in January 2021 after the Al-Ula Summit ending a three and a half year closure. 

ถามอีก กับคุณสุรนัย โรจน์วงศ์จรัต ประธานเจ้าหน้าที่บริหาร บมจ. สหไทยการพิมพ์และบรรจุภัณฑ์ (STP) คุยอะไรกันบ้าง? - Business Model - สัดส่วนรายได้ ลูกค้า - ผลประกอบการเติบโต - ความเสี่ยงการกระจุกตัวของลูกค้า - อัตราการทำกำไรลดลงช่วงโควิด - สามารถส่งผ่านต้นทุนให้ลูกค้าได้? - เป้าหมายการระดมทุน IPO - การแข่งขันดุเดือดแค่ไหน - ขยายไปลูกค้าต่างชาติไหม - จุดเด่นของ STP - IPO - อัตราส่วนทางการเงิน - วัตถุประสงค์การระดมทุน - Investment Highlights

Many have proven that investing in commercial real estate is always a good idea. In today's #Highlights episode, we look back at our conversations with successful real estate entrepreneurs Dr. Masaki Oishi and Terry Hale. They talk about the benefits of commercial real estate investing and how you can maximize your profit now!Masaki says for you to be successful in commercial real estate investing, you must choose your properties and sub-markets well, and it helps to have a plan. Meanwhile, Terry tells us why a shotgun approach isn't the best use of your time, and why laser focus is a must if you want to achieve success. Enjoy the show!

The Stock Day Podcast welcomed Tego Cyber Inc. (TGCB)(“the Company”), a company that was created to capitalize on the emerging cyber threat intelligence market. CEO of the Company, Shannon Wilkinson, joined Stock Day host Everett Jolly. 

Die Heidelberger Druckmaschinen Aktie zählt zu den absoluten Überfliegern der letzten 15 Monate - insgesamt erzielte die Aktie seitdem eine sagenhafte Rendite von 486%. Befeuert wurde die Rallye vor allem durch die sogenannten Wallboxen, die einen ganz neuen Markt erschließen. Head of Investor Relations Maximilan Beyer stellt sich allen Fragen und gibt Einblicke in die aktuelle Situation beim traditionsreichen Unternehmen. ⌚ Timestamps: (0:00 Intro (1:16) -- Beginn der Präsentation -- (4:21) Innovation als Erfolgsgrundlage (5:48) Hightech in traditionsreicher Branche - der smarte Printshop (6:58) Drei-Phasen-Modell zur Zukunftsausrichtung des Konzerns (7:26) Finanzielle Stabilität (11:15) Strategie (13:14) Starkes Kerngeschäft (17:13) Neues Wachstum (27:26) Investment Highlights (28:05) -- Beginn der Q&A-Session -- (29:33) Wie viele Mitarbeiter? (30:16) Wie kommt man darauf, Wallboxen herzustellen? (31:59) IPO zu Wallboxen geplant? (32:56) Ist Compleo Kunde oder Konkurrent? (33:44) Die größten Wettbewerber? (34:38) Unterschiede zu König & Bauer? (35:59) Lieferkettenprobleme und Konjunkturdellen? (36:56) Wie hoch sind die Umsätze bei Verpackungsdruck, digitalen Modellen und China? Wachstum? (38:08) Überschneidet sich das China-Geschäft mit anderen Bereichen? (39:08) Werden Patente selbst genutzt? (40:03) Welche Margen sind von nutzungsbasierten Geschäftsmodellen zu erwarten? (40:55) Wie viele Wallboxen werden pro Jahr produziert? (41:41) Wird es auch Wallboxen für den öffentlichen Raum geben? (42:26) Wie soll die Eigenkapitalquote erhöht werden? Kapitalerhöhung? (44:15) Wie hoch sind die Margen pro Wallbox? (44:40) Warum verkauft Heidelberg Boxen nicht direkt? (46:09) Kommen Sie wieder zum Anleger Forum? (46:56) Wie sehen die Nettogewinnerwartungen aus? (47:22) Wie hoch ist der durchschnittliche Zinssatz des Fremdkapitals? (48:18) Wie viele Mitarbeiter wurden zuletzt freigestellt? (49:33) Wie wollen Sie den Service-Umsatz in China steigern? (50:21) Sind Sie selbst Aktionär? (51:07) Antwortet der CFO Privatanlegern? (52:03) Anregung: Wallbox-Karton (52:43) Wann kann man mit einer Dividende rechnen? (53:47) Warum wurde bei 50 Cent kein Aktienrückkauf getätigt? (54:31) An welchen Kennzahlen kann man Heidelberg bewerten? (55:28) Ist bald mit einer neuen Wandelanleihe zu rechnen? (56:28) Ist eine Aktiendividende besser als eine Bardividende? (57:08) Anregung: Betriebsrente in Aktien tauschen (57:53) Wie wollen Sie die Kapitalmarktkommunikation verbessern? (58:55) Stand der Klage gegen Benpac? 59:35) Wie hoch ist der Break-Even-Umsatz? (1:00:48) Welchen Umsatz braucht es, um Kapitalkosten zu verdienen? (1:01:45) Wie kann man Privatanleger mehr für die Strategie begeistern? (1:03:01) Wurde der Käufer intensiv geprüft? (1:03:42) Wer hat die Verträge ausgehandelt? (1:04:07) Welche Gründe sprechen gegen eine Aktiendividende? (1:05:11) Wie sieht die Mitarbeiterfluktuation aus? (1:06:16) Darf man unter Nennwert Dividende ausschütten? (1:06:45) Hätte man Heidelberg übernehmen können? (1:07:45) Können Sie die Bilanz und Mitarbeiterentwicklung beim nächsten Forum mehr in den Fokus nehmen? (1:08:44) Was sind die Hauptgründe für ein Investment? (1:11:04) Warum kauft der Vorstand so wenige Aktien?  

Are you looking to protect your retirement with the best gold investment IRA solution? You're in the right place! Check out these options today at: https://bestgoldinvestmentreview.com (https://bestgoldinvestmentreview.com)

www.adamispharmaceuticals.com “Strong Buy” 12-month Price Target of $15 - $18 indicates a potential price gain of 224% to 269%* 22-page research report by Harbinger Research details Investment Opportunity, Valuation Comparables... includes Profit and Loss Models thru FY2022. Brian Connell, CFA Investment Highlights: Net $23.7 million in recent funding and NASDAQ up-listing constitutes “Major Corporate Milestones” – institutional and retail visibility greatly enhanced. First product (Epinephrine Pre-filled Syringe) ready for FDA 505(B)(2) filing soon - early ’15 approval likely, leading to $30 - $50 million in annual sales over next 2 – 3 years. Completed purchase of the 3M Taper Dry Powder Inhaler (DPI) technology in December 2013 – creating potential branded generic competitor for Glaxo-SmithKline (NYSE: GSK) and its $7.7 billion global market.  Two additional products will likely receive FDA approval in 2016 and 2017 - eventual annual revenues of $30 million or more expected for each. Revenues starting in FY2015, with rapid growth in FY2016, FY2017 and FY2018 - estimated at $16.75MM, $49.45MM and $93.12MM, respectively – all subject to FDA approvals and market conditions of course, but Adamis has certainly turned the corner as a “Developing Specialty Pharmaceuticals Co.” Four early stage biotech products focused on the treatment of prostate cancer - given that the Company’s current priority is “to get to market” with its specialty pharma products, the biotech segment could create a win-fall for investors through a spin-out, IPO, sale to a larger biotech firm, or through royalties/marketing partnerships. It’s like a free-call option for informed investors. Company Overview: Adamis is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer. *Based on market close, March 19, 2014

www.adamispharmaceuticals.com “Strong Buy” 12-month Price Target of $15 - $18 indicates a potential price gain of 224% to 269%* 22-page research report by Harbinger Research details Investment Opportunity, Valuation Comparables... includes Profit and Loss Models thru FY2022. Brian Connell, CFA Investment Highlights: Net $23.7 million in recent funding and NASDAQ up-listing constitutes “Major Corporate Milestones” – institutional and retail visibility greatly enhanced. First product (Epinephrine Pre-filled Syringe) ready for FDA 505(B)(2) filing soon - early ’15 approval likely, leading to $30 - $50 million in annual sales over next 2 – 3 years. Completed purchase of the 3M Taper Dry Powder Inhaler (DPI) technology in December 2013 – creating potential branded generic competitor for Glaxo-SmithKline (NYSE: GSK) and its $7.7 billion global market.  Two additional products will likely receive FDA approval in 2016 and 2017 - eventual annual revenues of $30 million or more expected for each. Revenues starting in FY2015, with rapid growth in FY2016, FY2017 and FY2018 - estimated at $16.75MM, $49.45MM and $93.12MM, respectively – all subject to FDA approvals and market conditions of course, but Adamis has certainly turned the corner as a “Developing Specialty Pharmaceuticals Co.” Four early stage biotech products focused on the treatment of prostate cancer - given that the Company’s current priority is “to get to market” with its specialty pharma products, the biotech segment could create a win-fall for investors through a spin-out, IPO, sale to a larger biotech firm, or through royalties/marketing partnerships. It’s like a free-call option for informed investors. Company Overview: Adamis is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer. *Based on market close, March 19, 2014

Panache is an alcoholic beverage company specializing in the development, global sales and marketing of spirits brands. Panache is following a unique “build and exit” business model. Existing portfolio contains three brands: Wodka Vodka, Alchemia Vodka and Alibi Whiskey. Investment Highlights: $10 million backlog for “Alibi American Whiskey” announced in December 2012 – exclusive two year national distribution agreement with Domaine Select Wine Estates, LLC Major spirits companies have largely abandoned grassroots developments of brands -  now favor an “acquire to grow” philosophy Panache’s niche is “build and exit” - development and global sales and marketing of unique spirits brands for acquisition Panache became import company of record for premium vodka 42 BELOW in late 2004 - Bacardi purchased the brand for $91 million two years later (representing a gain on sale of $71 million) $970 Billion Global Alcoholic Beverage Market – US is most important liquor market in the world, and this management team knows how to exploit it for maximum shareholder value 30-page Research Report Details Unique Business Model, Industry, Valuation... plus Income Statement and Financial Projections thru 2016.

Panache is an alcoholic beverage company specializing in the development, global sales and marketing of spirits brands. Panache is following a unique “build and exit” business model. Existing portfolio contains three brands: Wodka Vodka, Alchemia Vodka and Alibi Whiskey. Investment Highlights: $10 million backlog for “Alibi American Whiskey” announced in December 2012 – exclusive two year national distribution agreement with Domaine Select Wine Estates, LLC Major spirits companies have largely abandoned grassroots developments of brands -  now favor an “acquire to grow” philosophy Panache’s niche is “build and exit” - development and global sales and marketing of unique spirits brands for acquisition Panache became import company of record for premium vodka 42 BELOW in late 2004 - Bacardi purchased the brand for $91 million two years later (representing a gain on sale of $71 million) $970 Billion Global Alcoholic Beverage Market – US is most important liquor market in the world, and this management team knows how to exploit it for maximum shareholder value 30-page Research Report Details Unique Business Model, Industry, Valuation... plus Income Statement and Financial Projections thru 2016.

EnerJex is an E&P company with producing assets located in Eastern Kansas and South Texas. The Company is focused on the acquisition and development of shallow oil properties that have low production decline rates and offer abundant drilling opportunities with low risk profiles. Investment Highlights: Achieved 97.6% Drilling Success Rate - drilled 123 economically successful oil wells out of 126 wells drilled in its Kansas plays. Hundreds of Low-Risk Shallow Oil Drilling Opportunities Identified on Existing Properties - cash on cash IRR's on these wells often approaches or exceeds 50%. Shares currently trading at 50% discount to market value - ENRJ closed at $0.60 per share on Monday 4/1/2013. Market value projected to be $1.21. 29-page Research Report Details Current Market Valuation... leasehold positions, plus Income Statement and Financial Projections thru 2016.

EnerJex is an E&P company with producing assets located in Eastern Kansas and South Texas. The Company is focused on the acquisition and development of shallow oil properties that have low production decline rates and offer abundant drilling opportunities with low risk profiles. Investment Highlights: Achieved 97.6% Drilling Success Rate - drilled 123 economically successful oil wells out of 126 wells drilled in its Kansas plays. Hundreds of Low-Risk Shallow Oil Drilling Opportunities Identified on Existing Properties - cash on cash IRR's on these wells often approaches or exceeds 50%. Shares currently trading at 50% discount to market value - ENRJ closed at $0.60 per share on Monday 4/1/2013. Market value projected to be $1.21. 29-page Research Report Details Current Market Valuation... leasehold positions, plus Income Statement and Financial Projections thru 2016.